The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Broluzumab Biosimilars Market Research Report 2025
Synopsis
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Global Broluzumab Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Broluzumab Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Broluzumab Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Segment by Type
Beovu
Vsiqq
Others
Segment by Application
ARMD
Kaposi Sarcoma
Glioblastoma
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Broluzumab Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Global Broluzumab Biosimilars market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Broluzumab Biosimilars market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Broluzumab Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius
Segment by Type
Beovu
Vsiqq
Others
Segment by Application
ARMD
Kaposi Sarcoma
Glioblastoma
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Broluzumab Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Broluzumab Biosimilars Market Overview
1.1 Product Overview and Scope of Broluzumab Biosimilars
1.2 Broluzumab Biosimilars Segment by Type
1.2.1 Global Broluzumab Biosimilars Market Value Comparison by Type (2023-2029)
1.2.2 Beovu
1.2.3 Vsiqq
1.2.4 Others
1.3 Broluzumab Biosimilars Segment by Application
1.3.1 Global Broluzumab Biosimilars Market Value by Application: (2023-2029)
1.3.2 ARMD
1.3.3 Kaposi Sarcoma
1.3.4 Glioblastoma
1.4 Global Broluzumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Broluzumab Biosimilars Revenue 2018-2029
1.4.2 Global Broluzumab Biosimilars Sales 2018-2029
1.4.3 Global Broluzumab Biosimilars Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Broluzumab Biosimilars Market Competition by Manufacturers
2.1 Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global Broluzumab Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Broluzumab Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global Broluzumab Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Broluzumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Broluzumab Biosimilars, Product Type & Application
2.7 Broluzumab Biosimilars Market Competitive Situation and Trends
2.7.1 Broluzumab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Broluzumab Biosimilars Players Market Share by Revenue
2.7.3 Global Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Broluzumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Broluzumab Biosimilars Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Broluzumab Biosimilars Global Broluzumab Biosimilars Sales by Region: 2018-2029
3.2.1 Global Broluzumab Biosimilars Sales by Region: 2018-2023
3.2.2 Global Broluzumab Biosimilars Sales by Region: 2024-2029
3.3 Global Broluzumab Biosimilars Global Broluzumab Biosimilars Revenue by Region: 2018-2029
3.3.1 Global Broluzumab Biosimilars Revenue by Region: 2018-2023
3.3.2 Global Broluzumab Biosimilars Revenue by Region: 2024-2029
3.4 North America Broluzumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Broluzumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Broluzumab Biosimilars Sales by Country (2018-2029)
3.4.3 North America Broluzumab Biosimilars Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Broluzumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Broluzumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Broluzumab Biosimilars Sales by Country (2018-2029)
3.5.3 Europe Broluzumab Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Broluzumab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Broluzumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Broluzumab Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific Broluzumab Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Broluzumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Broluzumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Broluzumab Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America Broluzumab Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Broluzumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Broluzumab Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Broluzumab Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa Broluzumab Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Broluzumab Biosimilars Sales by Type (2018-2029)
4.1.1 Global Broluzumab Biosimilars Sales by Type (2018-2023)
4.1.2 Global Broluzumab Biosimilars Sales by Type (2024-2029)
4.1.3 Global Broluzumab Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global Broluzumab Biosimilars Revenue by Type (2018-2029)
4.2.1 Global Broluzumab Biosimilars Revenue by Type (2018-2023)
4.2.2 Global Broluzumab Biosimilars Revenue by Type (2024-2029)
4.2.3 Global Broluzumab Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global Broluzumab Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global Broluzumab Biosimilars Sales by Application (2018-2029)
5.1.1 Global Broluzumab Biosimilars Sales by Application (2018-2023)
5.1.2 Global Broluzumab Biosimilars Sales by Application (2024-2029)
5.1.3 Global Broluzumab Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global Broluzumab Biosimilars Revenue by Application (2018-2029)
5.2.1 Global Broluzumab Biosimilars Revenue by Application (2018-2023)
5.2.2 Global Broluzumab Biosimilars Revenue by Application (2024-2029)
5.2.3 Global Broluzumab Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global Broluzumab Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novartis Broluzumab Biosimilars Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Corporation Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Genentech Broluzumab Biosimilars Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche Broluzumab Biosimilars Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Broluzumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sartorius Broluzumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Eli Lilly Broluzumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bayer Broluzumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Amgen Broluzumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PlantForm Broluzumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 PharmaPraxis Broluzumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Broluzumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Samsung Bioepis Broluzumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Broluzumab Biosimilars Description and Business Overview
6.12.3 Centus Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Centus Broluzumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Broluzumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Dr Reddy's Broluzumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Broluzumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Aurobindo Pharma Broluzumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Broluzumab Biosimilars Description and Business Overview
6.16.3 Biocad Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Biocad Broluzumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Broluzumab Biosimilars Description and Business Overview
6.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.17.4 MAbxience Broluzumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Broluzumab Biosimilars Description and Business Overview
6.18.3 Hetero Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Hetero Broluzumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Broluzumab Biosimilars Description and Business Overview
6.19.3 Biocon Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Biocon Broluzumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Broluzumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kirin Biologics Broluzumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Broluzumab Biosimilars Description and Business Overview
6.21.3 Mylan Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Mylan Broluzumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Broluzumab Biosimilars Description and Business Overview
6.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.22.4 BeiGene Broluzumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Broluzumab Biosimilars Description and Business Overview
6.23.3 Innovent Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Innovent Broluzumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Broluzumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.27.4 TOT BIOPHARM Broluzumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.28.4 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Broluzumab Biosimilars Description and Business Overview
6.29.3 Henlius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.29.4 Henlius Broluzumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Broluzumab Biosimilars Industry Chain Analysis
7.2 Broluzumab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Broluzumab Biosimilars Production Mode & Process
7.4 Broluzumab Biosimilars Sales and Marketing
7.4.1 Broluzumab Biosimilars Sales Channels
7.4.2 Broluzumab Biosimilars Distributors
7.5 Broluzumab Biosimilars Customers
8 Broluzumab Biosimilars Market Dynamics
8.1 Broluzumab Biosimilars Industry Trends
8.2 Broluzumab Biosimilars Market Drivers
8.3 Broluzumab Biosimilars Market Challenges
8.4 Broluzumab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
